Oxybutynin treatment for hyperhidrosis: a comparative analysis between genders

Wolosker, Nelson; Krutman, Mariana; Campdell, Taiz Pereira Donozo Almeida; Kauffman, Paulo; Campos, José Ribas Milanez de; Puech-Leão, Pedro

doi:10.1590/s1679-45082012000400002

Cited by 30 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,12,14 This improvement was demonstrated by both objective measurements 13 and patient questionnaire assessments. [7][8][9][10][11][12][13][15][16][17][18][19][20][21][22] Oxybutynin therapy does not demonstrate tachyphylaxis and patients continued to note symptom improvement in long-term studies. 15,[20][21][22] Methantheline bromide therapy for primary hyperhidrosis was assessed in a single randomized controlled trial 29 and showed a decrease in the symptoms of hyperhidrosis using both subjective (HDSS scoring) and objective (gravimetry) measures.…”

Section: Search Methods and Selection Of Studiesmentioning

confidence: 99%

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off-license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty-three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60-97%) patients and improved QOL in 75.6% (range 57.6-100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in HDSS score and 40.9% increase in DLQI score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3-100%) of participants taking oxybutynin 10 mg/day, 38.6% (range 27.8-63.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.

show abstract

Section: Search Methods and Selection Of Studiesmentioning

confidence: 99%

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…40 When comparing the treatment outcome related to gender, there was no significant difference in improvement, with symptoms relief in about 70% in both groups. 41 Nor overweight or obesity was considered limiting factors for treatment, as 67.8% of patients with overweight and 63% obese showed significant clinical improvement. 42 When patients over 40 years were analyzed, 48 subjects between 40-49 years and 39 patients older than 50 years had significant improvement (75% in the first group and 87.2% in the second), with emphasis to the fact that most of the older patients had a high level of improvement.…”

Section: Resultsmentioning

confidence: 99%

Oxybutynin as an alternative treatment for hyperhidrosis

Delort

Marchi

Corrêa

2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

Hyperhidrosis is the excessive production of sweating, which can be primary and focal or secondary to various pathologies. The exact cause of primary focal hyperhidrosis is still unknown, although a genetic basis is recognized, and its prevalence varies from 1% to 2.8%. The most affected sites are the armpits, palms, soles and face. It causes much discomfort, affects the quality of life, and is estimated to be undervalued by health professionals. Many treatment options are proposed, both clinical and surgical. The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to control overactive bladder.

show abstract

“…The difference in the efficacy of oxybutynin has been reported to be statistically nonsignificant when comparing gender [33]. A retrospective analysis reported that 67% of men and 70% of women with primary focal hyperhidrosis who were treated with oxybutynin reported partial or greater improvement.…”

Section: Efficacy In Special Population Groupsmentioning

confidence: 99%

“…Over 70% of the women in the study comparing the differences of oxybutynin treatment between genders classified their QOL as ‘very poor' prior to treatment, which demonstrates that women, in addition to seeking medical assistance more frequently, are also more affected by hyperhidrosis than men. On the other hand, women benefited the most from oxybutynin treatment, presenting a ‘great improvement' in the level of hyperhidrosis in over 40% of the cases [33]. …”

Section: Improvement In Qolmentioning

confidence: 99%

Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art

Campanati

Gregoriou

Kontochristopoulos

et al. 2015

Skin Appendage Disord

View full text Add to dashboard Cite

Oxybutynin is an anticholinergic drug with an emerging role in the treatment of hyperhidrosis. Several recent studies have documented that it is effective both in focal and generalized hyperhidrosis and shows universally good response among different groups of patients regardless of age, gender, and weight. The most common adverse event is dry mouth reported by almost all patients treated. The way this might affect long-term compliance and tolerability should be better investigated in the future.

show abstract

Oxybutynin treatment for hyperhidrosis: a comparative analysis between genders

Abstract: Gender is not a factor that significantly interferes in oxybutynin treatment results. Quality of life indices and clinical improvement level were similar in men and women.

Cited by 30 publications

References 13 publications

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Oxybutynin as an alternative treatment for hyperhidrosis

Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art

Contact Info

Product

Resources

About